The senior management consists of the Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Chief Scientific Officer, Chief Commercial Officer, Chief Medical Officer, Director of Corporate Affairs and Head of Human Resources.
Monica Shaw, MD
Chief Executive Officer
Monica Shaw was appointed Chief Executive Officer in 2023.
Monica is a Medical Doctor with breadth of leadership experience. She was Executive Vice President, Head Europe/Canada and Global Marketing Psoriasis, LEO Pharma 2020-2022. She was VP and Head of Asia Pacific Region for GSK/ViiV Healthcare Singapore 2018-2020, General Manager GSK Panama, 2016-2018 and VP Global Franchise Head for Specialty, GSK 2014-2016. Prior to that she held managerial roles in Medical Affairs and Clinical Development for several pharmaceutical companies, and worked as a Medical Doctor.
Monica took a MBBS MA, Medical Degree at Oxford University in 2002, and became a Member of the Royal College of Physicians in UK in 2005.
Holdings in Oncopeptides: 882,448 share awards*
Other current positions: Non-executive Board Director, AC Immune
Eva Nordström, MSc Pharm
Chief Operating Officer (COO) and Deputy Managing Director
Eva Nordström was appointed as Head of Clinical Development in 2012, Chief Operating Officer 2020 and Deputy Managing Director 2021. Eva is responsible for strategic and operational deliveries in Biometrics, CMC, Clinical Operations, Global Drug Supply and Preclinical Operations.
Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.
Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.
Holdings in Oncopeptides: 120,200 shares, 158,369 share awards* and 284,113 options*.
Other current positions: Board member of Oxcia AB, Alternate Director of Utilica AB.
Holger Lembrér, MSc
Chief Financial Officer (CFO)
Holger was appointed CFO in 2023 and is responsible for Finance, Legal, IT and administration.
Holger has a wide range of experience from several different positions in finance and before he assumed his role at Oncopeptides, he was CFO for a global business area within the ASSA ABLOY Group 2021-2022. Previously, Holger held several other positions within the ASSA ABLOY Group during 2011-2021, such as Investor Relations Officer and Financial Controller. He has also worked as an auditor at Ernst & Young.
Holger holds a Master of Science degree in Business and Economics, from the University of Uppsala, Sweden.
Holdings in Oncopeptides: 58,504 share awards*
Other current positions: -
Director of Corporate Affairs
David Augustsson joined the company as Director of Corporate Affairs in 2023 and is responsible for corporate strategy, brand and communication.
David has a broad background from leading strategic communication in international, listed companies both as a consultant and in-house. Between 2016-2023 he worked for global fintech company Nasdaq, where he during the last three years was responsible for the company´s European communication, including seven national stock exchanges, as well as its global efforts within market technology and carbon removal. He has also worked as a consultant at agencies including Prime WeberShandwick and Hill+Knowlton.
David holds a Master in Science in International Business and Management from Uppsala University and Wirtschaftsuniversität Wien.
Holdings in Oncopeptides: -
Other current positions: -
Jakob Lindberg, Med Lic
Chief Scientific Officer (CSO)
Jakob Lindberg was appointed CSO in 2023.
Jakob Lindberg was the CEO of Oncopeptides from the restart of the company in 2011, until June 2020, as well as from November 2021 until January 2023. During July 2020 until November 2021 he was the CSO of Oncopeptides. His previous roles include being an analyst at Merrill Lynch & Co and a consultant at McKinsey & Co. Jakob was co-founder of Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.
Jakob has studied medicine at the Karolinska Institute. He gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from the Stockholm University.
Holdings in Oncopeptides: 868,331 shares (853,031 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB), 391,922 share awards* and 605,081 options*.
Other current positions: CEO of Oncopeptides, Inc, director of Oncopeptides Incentive AB, director of Affibody Medical AB, Camurus AB and Lindberg Life-Science AB. CEO of Lindberg Life-Science AB.
Klaas Bakker, MD, PhD
Head of R&D and Chief Medical Officer (CMO)
Klaas Bakker was appointed as Chief Medical Officer in 2019 and Head of Research and Development in 2022. In this role he is accountable for the Research and Clinical Development Strategy, Regulatory Affairs, Pharmacovigilance and Medical Affairs.
Klaas has previously held various roles at AstraZeneca within their global Oncology Business Unit, including Vice President Medical Affairs of the Global TAGRISSO-TDR Franchise in Oncology, where he was responsible for several drugs, including AstraZeneca’s drug osimertinib.
Klaas holds an MD and is a board-certified neurosurgeon from the university of Groningen, the Netherlands, where he was clinically active until 2015. In addition, he holds a PhD in Immuno-Hematology and has authored over 50 publications in international peer-reviewed journals.
Holdings in Oncopeptides: 105,000 shares, 140,252 share awards* and 179,384 options*.
Other current positions: Director of Trust office foundation (STAK) AI-InfraSolutions
Head of Human Resources
Sara joined Oncopeptides in May 2018 as Head of Human Resources. Since May 2022, she is a member of the company’s leadership team.
Sara has a broad experience of HR and has held managerial positions in HR during the past 10 years. Before joining Oncopeptides, she worked in the financial industry at Neonet Securities AB.
Sara has studied the Human Resources program with a major in psychology at Örebro University and Stockholm University.
Holdings in Oncopeptides: 85 shares, 36,476 share awards* and 9,498 options*.
Sofia Heigis, MSc
Chief Commercial Officer, CCO, and Managing Director Germany
Sofia joined Oncopeptides in August 2020 as Senior Vice President and Global Head Medical Affairs. She was appointed Chief Commercial Officer and Managing Director Germany in 2022. Sofia was engaged in the preparedness and launch of Pepaxto in the US, and has led the preparations of the commercialization of Pepaxti in Europe. She has been a member of the Leadership Team since November 2021.
Sofia brings broad experience from leading international roles in Medical Affairs, Regulatory Affairs, Market Ethics, Pharmacovigilance, Real World Evidence as well as several Marketing and Sales roles at Astra Zeneca, and has been engaged in both global and local product launches.
Sofia holds a Master of Pharmacology from the University of Gothenburg, including a Master Thesis in Pharmacology from Bond University. She has an Executive Master in Strategy, and is a member of the business network for female leaders, Ruter Dam.
Holdings in Oncopeptides: 20,104 shares, 236,223 share awards* and 96,532 options*.
Other current positions: -
* The options and share awards entitles to one share per option in accordance with existing terms.
For more information and terms please read under Corporate Governance – Remuneration.
Holdings in Oncopeptides AB (publ) as of May 4, 2023.